MedTrace Logo

A Study of the Use of Chartis System to Optimize Subject Selection for Endobronchial Lung Volume Reduction (ELVR)

NCT01101958 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 96

Last updated 2017-05-12

Study results available
· View outcomes & findings →

Summary

Use of the Chartis® Assessment System prior to EBV Treatment

Conditions

  • Emphysema

Interventions

DEVICE

Chartis System

The Chartis System provides a value that represents the quantification of the average resistance to airflow through collateral airways.

DEVICE

Endobronchial Valve (EBV) Treatment

The endobronchial valve is designed to induce target lobe volume reduction.

Sponsors & Collaborators

  • Pulmonx Corporation

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2013-03-31
Completion
2013-03-31

Countries

  • Germany
  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01101958 on ClinicalTrials.gov